One2Treat’s Post

In case you missed it, I encourage you to read Applied Clinical Trials Magazine's October feature on the pronounced site consolidation trend that is emerging in drug development. It shares in-depth reporting and analysis of the potential advantages/disadvantages—and includes compelling survey findings from co-authors (and top industry leaders in the field) Gerri Anselmo-Gallagher, Adam Kinsey, Mark Scullion, and Samir Shah. Beyond the exclusive data, the group also provides a valuable site-selection guide for this new landscape, with its “13 key attributes to consider” in a viewer-friendly chart. Click on the link below or, to view the digital version, click the top left teaser on our cover here: bit.ly/40tBu03 

📰 Today in PharmaTimes Media Ltd, our Founder and President Gen Li, PhD, MBA discusses the new age of #ClinicalTrials. With nearly a third of phase II trials terminated in 2023, Gen highlights that sponsors must adopt a data-driven approach to improve success rates. 📈 Gen explains how Digital Patient Profiles and Digital Trial Arms help to reduce operational costs, improve patient-centricity, and get life-saving therapies to those who need them faster. 💊 👀 Check out the full article, here. https://lnkd.in/ebPG2P77

To wrap up their three-part series, Kym Denny Eves and Liam Eves discuss how various drug candidates come inherent with barriers to adoption that directly impact how participants and providers engage with clinical research. They also offer ways to clear these hurdles for faster, less costly trials. #clinicaltrials #clinicalresearch

In a very exciting new contribution to Pharma's Almanac, YourBio Health's Hutan Ashrafian, M.D., Ph.D., MBA, discusses the industry's transition toward decentralized clinical trials, evolving challenges like industry conservatism and technology integration, and the emergence of innovative, patient-centric blood collection solutions like YourBio Health's TAP Micro Select. #pharma #clinicaltrials #decentralizedtrials #bloodcollection #remotesampling

📣 New data from the Tufts Center for the Study of Drug Development (CSDD)’s PACT Consortium links DCT approaches to notably higher participation rates across multiple demographic groups. The new research shows that a more strategic implementation of DCT approaches in conjunction with more regulatory rigor can meaningfully shift diversity metrics in clinical research 🌍. 👉 Read here: https://lnkd.in/eKyvw2Ed ________ Michelle Longmire, Tim Smith, Pamela Tenaerts, MD, MBA, Cindy Howry, MS, Alison Holland, Jena Daniels, Steve Jones #clinicaltrials #clinicalresearch #healthcare #decentralizedtrials

🎯 Revolutionizing Clinical Trial Design: Enhancing Success Probability 🎯 In the intricate world of clinical trials, the ultimate objective is to demonstrate a drug's safety and efficacy. However, the journey to this outcome is influenced by factors that go beyond the molecule itself. At Lexidyne, we focus on optimizing these controllable factors to maximize the probability of success while meeting financial and logistical constraints. 🔍 Key Factors We Address: - Patient Screening & Selection: Leveraging advanced trial participant screening models to minimize the placebo effect of self-reported outcomes while ensuring diverse and representative patient groups. - Trial Site Selection: Using predictive analytics to identify optimal trial locations in the context of other ongoing or pending studies, enhancing recruitment speed and reliability. - PTRS Handicapping: Predicting the phase-by-phase probability of technical and regulatory success for pending trials based on the unique combination of therapy attributes. - Dynamic Monitoring: Real-time overlays of ongoing trials to adjust for competitive landscapes and evolving market dynamics. - Market Integration: Combining clinical trial data with broader market simulations to understand potential post-launch impacts. 💡 Our proprietary Portfolio Virtualization approach integrates Monte Carlo simulations, real options analysis, and AI-driven optimization. This framework enables: - Transparent metric evaluation of trial designs. - Scenario-based strategy development to minimize regret and maximize resource utilization. - Strategic decision-making under constraints like cost, capacity, and timeline. The Lexidyne Clinical Trial Digest is a weekly newsletter that provides insight into key milestones in ongoing clinical trials. This digest includes: ·      Summary of milestone outcomes by disease area. ·      Comprehensive coverage of all assets currently in clinical trials. ·      Key information points that may impact future market dynamics. By refining these elements, we can ensure that trial outcomes reflect a drug's true potential, free from confounding variables. The result? A fair assessment of efficacy and safety, laying a solid foundation for success. #ClinicalTrials #PatientScreening #TrialSiteSelection #DynamicMonitoring #PortfolioVirtualization #AIOptimization #MonteCarloSimulation #PharmaceuticalInnovation #HealthcareInnovation #StrategicDecisionMaking #Lexidyne

🎯 Revolutionizing Clinical Trial Design: Enhancing Success Probability 🎯 In the intricate world of clinical trials, the ultimate objective is to demonstrate a drug's safety and efficacy. However, the journey to this outcome is influenced by factors that go beyond the molecule itself. At Lexidyne, we focus on optimizing these controllable factors to maximize the probability of success while meeting financial and logistical constraints. 🔍 Key Factors We Address: - Patient Screening & Selection: Leveraging advanced trial participant screening models to minimize the placebo effect of self-reported outcomes while ensuring diverse and representative patient groups. - Trial Site Selection: Using predictive analytics to identify optimal trial locations in the context of other ongoing or pending studies, enhancing recruitment speed and reliability. - PTRS Handicapping: Predicting the phase-by-phase probability of technical and regulatory success for pending trials based on the unique combination of therapy attributes. - Dynamic Monitoring: Real-time overlays of ongoing trials to adjust for competitive landscapes and evolving market dynamics. - Market Integration: Combining clinical trial data with broader market simulations to understand potential post-launch impacts. 💡 Our proprietary Portfolio Virtualization approach integrates Monte Carlo simulations, real options analysis, and AI-driven optimization. This framework enables: - Transparent metric evaluation of trial designs. - Scenario-based strategy development to minimize regret and maximize resource utilization. - Strategic decision-making under constraints like cost, capacity, and timeline. The Lexidyne Clinical Trial Digest is a weekly newsletter that provides insight into key milestones in ongoing clinical trials. This digest includes: ·      Summary of milestone outcomes by disease area. ·      Comprehensive coverage of all assets currently in clinical trials. ·      Key information points that may impact future market dynamics. By refining these elements, we can ensure that trial outcomes reflect a drug's true potential, free from confounding variables. The result? A fair assessment of efficacy and safety, laying a solid foundation for success. #ClinicalTrials #PatientScreening #TrialSiteSelection #DynamicMonitoring #PortfolioVirtualization #AIOptimization #MonteCarloSimulation #PharmaceuticalInnovation #HealthcareInnovation #StrategicDecisionMaking #Lexidyne

At Miami Clinical Research, we're fast-tracking medical breakthroughs with cutting-edge clinical trials. Curious about how we turn lab innovations into life-saving treatments? Learn more about the processes and technology driving faster, cost-effective trials in our latest blog. Click the link below to explore: https://lnkd.in/gdFDEWta #medicalresearch #clinicaltrials #medicalstudies #miamiclinicalresearch #pharmaceuticaladvancements #clinicalinnovation #drugdevelopment #pharmaceuticalindustry #acceleratedtrials #healthcareinnovation 

Experience the synergy of expertise and innovation at Miami Clinical Research, where our dedicated professionals merge deep knowledge with state-of-the-art technology to propel crucial studies forward. Explore our latest blog post and uncover how we're reshaping the landscape of clinical trials: https://lnkd.in/g_XFQeBr #medicalresearch #clinicaltrials #medicalstudies #miamiclinicalresearch #clinicalresearch #pharmaceuticalinnovation #pharmaceuticalstudies